Print

HIVNET 007

A Phase I Study of the Safety and Immunogenicity of Live Recombinant ALVAC-HIV vCP205 in HIV-1 Uninfected Volunteers in Uganda

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) February 08, 1999
ALVAC-HIV MN120TMG strain (vCP205) Canarypox Env gp120, TM gp41, gag, protease B MN/LAI
ALVAC-HIV MN120TMG strain (vCP205) Viral Vector - Pox
Uganda 40
NCT00007423
https://www.clinicaltrials.gov/ct2/show/NCT00007423